论文部分内容阅读
目的观察氯吡格雷治疗不稳定型心绞痛(UAP)的临床疗效及安全性。方法选择诊断明确的不稳定型心绞痛患者59例,随机分为治疗组和对照组。对照组采用低分子肝素、阿司匹林及其他抗心绞痛药物,治疗组在以上治疗的基础上加用氯吡格雷首次顿服300mg。次日起75mg/天,连服两周。结果治疗组能明显减少心绞痛发作频率(P<0.05),改善临床症状,对改善缺血性ST段压低明显优于对照组(P<0.05),且对出凝血指标影响不大(P>0.05)。结论在常规抗心绞痛治疗基础上加用氯吡格雷对UAP更有效,而且安全。
Objective To observe the clinical efficacy and safety of clopidogrel in the treatment of unstable angina pectoris (UAP). Methods Fifty-nine patients with unstable angina pectoris were selected and randomly divided into treatment group and control group. Control group using low molecular weight heparin, aspirin and other anti-angina drugs, the treatment group on the basis of the above treatment plus clopidogrel for the first time serving Dayton 300mg. The next day 75mg / day, and even served two weeks. Results The treatment group could significantly reduce the frequency of angina pectoris (P <0.05), improve the clinical symptoms, and improve the ischemic ST segment depression significantly better than the control group (P <0.05), and had little effect on the coagulation index (P> 0.05 ). Conclusion The addition of clopidogrel to conventional anti-anginal therapy is more effective and safe for UAP.